|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12345678910111213...156157» |
- | Trial completion date, Trial primary completion date: APRAN: Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA. (clinicaltrials.gov) - Jul 17, 2018
P=N/A, N=100, Recruiting, Sponsor: Isabelle Fortin
Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Mar 2018 --> Mar 2019
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: Detemir: Role in Type 1 Diabetes (clinicaltrials.gov) - Jul 17, 2018
P4, N=18, Completed, Sponsor: Montefiore Medical Center
Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Mar 2018 --> Mar 2019 N=13 --> 18
- Promacta (eltrombopag) / Novartis
Enrollment change, Trial termination: End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia (clinicaltrials.gov) - Jul 17, 2018
P=N/A, N=35, Terminated, Sponsor: Weill Medical College of Cornell University
N=13 --> 18 N=20 --> 35 | Recruiting --> Terminated
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change, Trial termination: Dex/Rituxan: A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone (clinicaltrials.gov) - Jul 16, 2018
P=N/A, N=72, Terminated, Sponsor: Weill Medical College of Cornell University
N=20 --> 35 | Recruiting --> Terminated N=50 --> 72 | Recruiting --> Terminated
- | Promacta (eltrombopag) / Novartis
Enrollment change, Trial completion date, Trial primary completion date: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) (clinicaltrials.gov) - Jul 16, 2018
P2, N=18, Completed, Sponsor: Fondazione Progetto Ematologia
N=50 --> 72 | Recruiting --> Terminated N=26 --> 18 | Trial completion date: Jun 2015 --> Jun 2018 | Trial primary completion date: Jun 2015 --> Jun 2018
- | Trial completion, Trial completion date, Trial primary completion date, Compliance: Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ? (clinicaltrials.gov) - Jul 12, 2018
P=N/A, N=120, Completed, Sponsor: University Hospital, Brest
N=26 --> 18 | Trial completion date: Jun 2015 --> Jun 2018 | Trial primary completion date: Jun 2015 --> Jun 2018 Recruiting --> Completed | Trial completion date: Sep 2018 --> Jan 2018 | Trial primary completion date: Sep 2018 --> Jan 2018
- | Trial completion date, Trial primary completion date: Use of the Nine Holes Peg Test in Multiple Sclerosis: Participation of Elementary Neurological Components in the Functional Evaluation of Manual Dexterity (clinicaltrials.gov) - Jul 12, 2018
P=N/A, N=30, Recruiting, Sponsor: Brugmann University Hospital
Recruiting --> Completed | Trial completion date: Sep 2018 --> Jan 2018 | Trial primary completion date: Sep 2018 --> Jan 2018 Trial completion date: Mar 2018 --> Jan 2020 | Trial primary completion date: Mar 2018 --> Jan 2020
- | Biomarker, Enrollment closed, Enrollment change: A Pilot Study of Biomarkers of Stress in Youth Who Use Teens.Connect (clinicaltrials.gov) - Jul 12, 2018
P=N/A, N=29, Active, not recruiting, Sponsor: Yale University
Trial completion date: Mar 2018 --> Jan 2020 | Trial primary completion date: Mar 2018 --> Jan 2020 Recruiting --> Active, not recruiting | N=60 --> 29
- | Trial completion: Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index (clinicaltrials.gov) - Jul 12, 2018
P=N/A, N=15, Completed, Sponsor: Sansum Diabetes Research Institute
Recruiting --> Active, not recruiting | N=60 --> 29 Recruiting --> Completed
- | polyTregs / National Institute of Allergy and Infectious Diseases
Trial completion: T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs (clinicaltrials.gov) - Jul 11, 2018
P1, N=16, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Active, not recruiting --> Completed
- | gerilimzumab (ARGX-109) / argenx
Enrollment change, Trial withdrawal: Study Evaluating Gerilimzumab (clinicaltrials.gov) - Jul 11, 2018
P2, N=0, Withdrawn, Sponsor: Bird Rock Bio, Inc.
Active, not recruiting --> Completed N=200 --> 0 | Not yet recruiting --> Withdrawn
- ||||| TNFcept (etanercept biosimilar) / LG Chem, Mochida
Trial completion, Trial primary completion date: A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX) (clinicaltrials.gov) - Jul 6, 2018
P3, N=148, Completed, Sponsor: LG Life Sciences
N=200 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Dec 2017
- | Trial completion, Trial completion date, Trial primary completion date: Sleep, Coping and Executive Functioning in Youth With Type 1 Diabetes (clinicaltrials.gov) - Jul 2, 2018
P=N/A, N=40, Completed, Sponsor: Yale University
Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Dec 2017 Enrolling by invitation --> Completed | Trial completion date: Dec 2017 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018
- | Trial completion, Enrollment change: Arthritis Health Journal Proof of Concept Study (clinicaltrials.gov) - Jun 29, 2018
P=N/A, N=95, Completed, Sponsor: University of British Columbia
Enrolling by invitation --> Completed | Trial completion date: Dec 2017 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018 Active, not recruiting --> Completed | N=50 --> 95
- | Trial completion: Multiple Sclerosis and Pilates (clinicaltrials.gov) - Jun 28, 2018
P=N/A, N=30, Completed, Sponsor: University of Saskatchewan
Active, not recruiting --> Completed | N=50 --> 95 Recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: DP3: Tissue-Specific Metabolic Reprogramming in Diabetic Complications (clinicaltrials.gov) - Jun 28, 2018
P=N/A, N=35, Completed, Sponsor: University of Michigan
Recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2018 --> Aug 2017 | Trial primary completion date: May 2018 --> Aug 2017
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, Enrollment change, Patient reported outcomes: PROmyBETAapp: Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=96, Completed, Sponsor: Bayer
Recruiting --> Completed | Trial completion date: Dec 2018 --> Aug 2017 | Trial primary completion date: May 2018 --> Aug 2017 Recruiting --> Completed | N=40 --> 96
- ||| Trial completion, Trial completion date: Vanguard Complete Knee Versus Vanguard High Flex Rotating Platform (RP) Knee Study (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=300, Completed, Sponsor: Zimmer Biomet
Recruiting --> Completed | N=40 --> 96 Active, not recruiting --> Completed | Trial completion date: Oct 2021 --> Oct 2017
- | Trial completion: Power Over Pain (POP) Study (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=177, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed | Trial completion date: Oct 2021 --> Oct 2017 Active, not recruiting --> Completed
- ||| Trial completion: A Prospective Munti-center Study on VANGUARD™ PS Total Knee Replacement System (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=100, Completed, Sponsor: Zimmer Biomet
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion date: G7 Acetabular System vs. Exceed ABT Acetabular System in THA (clinicaltrials.gov) - Jun 26, 2018
P=N/A, N=160, Active, not recruiting, Sponsor: Zimmer Biomet
Active, not recruiting --> Completed Trial completion date: May 2018 --> Dec 2018
- || elcubragistat (Lu AG06466) / Lundbeck
Enrollment closed, Trial completion date, Trial primary completion date: Central Pain Study for ABX-1431 (clinicaltrials.gov) - Jun 26, 2018
P1, N=32, Active, not recruiting, Sponsor: Abide Therapeutics
Trial completion date: May 2018 --> Dec 2018 Recruiting --> Active, not recruiting | Trial completion date: Feb 2018 --> Sep 2018 | Trial primary completion date: Feb 2018 --> Aug 2018
- || Enrollment closed, Trial completion date, Trial primary completion date: VALUE: Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 21, 2018
P=N/A, N=80, Active, not recruiting, Sponsor: Lupus Research Alliance
Recruiting --> Active, not recruiting | Trial completion date: Feb 2018 --> Sep 2018 | Trial primary completion date: Feb 2018 --> Aug 2018 Recruiting --> Active, not recruiting | Trial completion date: May 2018 --> Sep 2018 | Trial primary completion date: Mar 2018 --> Jul 2018
- | Trial completion: Neurocognitive Impact of Hypoglycemia in Type 1 Diabetes (clinicaltrials.gov) - Jun 18, 2018
P=N/A, N=187, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting | Trial completion date: May 2018 --> Sep 2018 | Trial primary completion date: Mar 2018 --> Jul 2018 Active, not recruiting --> Completed
- | Trial completion, HEOR: IQAN: Intervention to Improve Quality of Life in African American Lupus Patients (clinicaltrials.gov) - Jun 15, 2018
P=N/A, N=153, Completed, Sponsor: Medical University of South Carolina
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment change, Trial termination: Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus (clinicaltrials.gov) - Jun 15, 2018
P1/2, N=30, Terminated, Sponsor: University of Nebraska
Active, not recruiting --> Completed N=10 --> 30 | Enrolling by invitation --> Terminated; Per Coordinator: study was closed and no cadaveric implants were performed
- | Trial completion, Trial completion date: FREE: A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes (clinicaltrials.gov) - Jun 15, 2018
P=N/A, N=10, Completed, Sponsor: University of Illinois at Chicago
N=10 --> 30 | Enrolling by invitation --> Terminated; Per Coordinator: study was closed and no cadaveric implants were performed Active, not recruiting --> Completed | Trial completion date: May 2018 --> Jan 2018
- | Apidra (insulin glulisine) / Sanofi
Trial completion: SHAN: Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children (clinicaltrials.gov) - Jun 14, 2018
P2, N=24, Completed, Sponsor: University Hospital, Montpellier
Active, not recruiting --> Completed | Trial completion date: May 2018 --> Jan 2018 Recruiting --> Completed
- | Trial completion: SONORE: Role of Ultrasound for Evaluating Rheumatoid Arthritis in Remission (clinicaltrials.gov) - Jun 11, 2018
P=N/A, N=116, Completed, Sponsor: University Hospital, Montpellier
Recruiting --> Completed Recruiting --> Completed
- | Trial primary completion date: Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation (clinicaltrials.gov) - Jun 6, 2018
P=N/A, N=600, Recruiting, Sponsor: Rodolfo Alejandro
Recruiting --> Completed Trial primary completion date: Apr 2019 --> Apr 2020
- | Trial completion, Trial completion date, Trial primary completion date, Immunomodulating: Transplantation of Autologous Stem Cells for the Treatment of Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 6, 2018
P1/2, N=100, Completed, Sponsor: Stem Cells Arabia
Trial primary completion date: Apr 2019 --> Apr 2020 Recruiting --> Completed | Trial completion date: Jan 2019 --> May 2018 | Trial primary completion date: Aug 2018 --> Aug 2017
- ||| Trial completion: The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01) (clinicaltrials.gov) - Jun 6, 2018
P=N/A, N=24, Completed, Sponsor: University of Cambridge
Recruiting --> Completed | Trial completion date: Jan 2019 --> May 2018 | Trial primary completion date: Aug 2018 --> Aug 2017 Recruiting --> Completed
- | Trial primary completion date, HEOR: Effects of Structured Group Education on Quality of Life and Glycemic Control in Type 1 Diabetes (clinicaltrials.gov) - Jun 4, 2018
P=N/A, N=72, Terminated, Sponsor: Azienda Ospedaliero-Universitaria Careggi
Recruiting --> Completed Trial primary completion date: Dec 2016 --> Jan 2018
- tabalumab (LY2127399) / Eli Lilly
Trial termination: Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jun 3, 2018
P3, N=8, Terminated, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2016 --> Jan 2018 Completed --> Terminated; Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773)
- tabalumab (LY2127399) / Eli Lilly
Biomarker, Enrollment change, Trial termination, Biopsy: A Study of LY2127399 in Rheumatoid Arthritis (clinicaltrials.gov) - Jun 3, 2018
P2, N=2, Terminated, Sponsor: Eli Lilly and Company
Completed --> Terminated; Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773) N=36 --> 2 | Completed --> Terminated; Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773).
- | fluvastatin / Generic mfg.
Trial completion, Enrollment change: Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients (clinicaltrials.gov) - Jun 3, 2018
P2, N=41, Completed, Sponsor: Hospital for Special Surgery, New York
N=36 --> 2 | Completed --> Terminated; Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773). Active, not recruiting --> Completed | N=60 --> 41
- | Trial completion date, Trial primary completion date: Diabeloop WP7 : Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop (WP7) (clinicaltrials.gov) - Jun 3, 2018
P=N/A, N=71, Active, not recruiting, Sponsor: Centre d
Active, not recruiting --> Completed | N=60 --> 41 Trial completion date: Mar 2018 --> Aug 2018 | Trial primary completion date: Feb 2018 --> Aug 2018
- | Enrollment change, Trial withdrawal: WBV-JIA: Effect of Whole Body Vibration Therapy in Children With Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=0, Withdrawn, Sponsor: Children's Hospital of Eastern Ontario
Trial completion date: Mar 2018 --> Aug 2018 | Trial primary completion date: Feb 2018 --> Aug 2018 N=70 --> 0 | Completed --> Withdrawn
- | Diamyd (recombinant 65 kDa isoform of human glutamic acid decarboxylase) / Diamyd Medical
Enrollment change, Trial termination: DiViD: Diabetes Virus Detection Project, Intervention With GAD-alum (clinicaltrials.gov) - Jun 2, 2018
P2, N=6, Terminated, Sponsor: Oslo University Hospital
N=70 --> 0 | Completed --> Withdrawn N=60 --> 6 | Recruiting --> Terminated; Complications to procedure
- | Trial completion date, Trial suspension, Trial primary completion date: Resistance Exercise in Rheumatic Disease (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=10, Suspended, Sponsor: Johns Hopkins University
N=60 --> 6 | Recruiting --> Terminated; Complications to procedure Trial completion date: Jul 2018 --> Dec 2018 | Recruiting --> Suspended | Trial primary completion date: Jul 2018 --> Dec 2018
- ||| dimethyl fumarate / Generic mfg.
Trial completion date: An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jun 1, 2018
P3, N=225, Active, not recruiting, Sponsor: Biogen
Trial completion date: Jul 2018 --> Dec 2018 | Recruiting --> Suspended | Trial primary completion date: Jul 2018 --> Dec 2018 Trial completion date: Oct 2019 --> Oct 2018
- | Trial completion, Trial completion date, Trial primary completion date: EPICOM: Study of Offspring of Women With Type 1 Diabetes (clinicaltrials.gov) - Jun 1, 2018
P=N/A, N=584, Completed, Sponsor: Odense University Hospital
Trial completion date: Oct 2019 --> Oct 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Dec 2017 | Trial primary completion date: Apr 2015 --> Nov 2017
- | Trial completion date, Trial primary completion date: PRESSRA: The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis (clinicaltrials.gov) - Jun 1, 2018
P=N/A, N=50, Suspended, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Dec 2017 | Trial primary completion date: Apr 2015 --> Nov 2017 Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018
- | Trial completion, Trial completion date, Trial primary completion date: Implementing Physical Activity Guidelines for Adults With MS (clinicaltrials.gov) - Jun 1, 2018
P=N/A, N=94, Completed, Sponsor: McMaster University
Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018 Recruiting --> Completed | Trial completion date: Mar 2017 --> Mar 2018 | Trial primary completion date: Dec 2016 --> Mar 2018
- || bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Trial completion, Trial completion date: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Jun 1, 2018
P2, N=11, Completed, Sponsor: Immune Pharmaceuticals
Recruiting --> Completed | Trial completion date: Mar 2017 --> Mar 2018 | Trial primary completion date: Dec 2016 --> Mar 2018 Recruiting --> Completed | Trial completion date: Jul 2018 --> Apr 2018
- | Myasterix (CV-MG01) / CuraVac
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis (clinicaltrials.gov) - Jun 1, 2018
P2/3, N=0, Withdrawn, Sponsor: CuraVac
Recruiting --> Completed | Trial completion date: Jul 2018 --> Apr 2018 N=66 --> 0 | Trial completion date: Dec 2018 --> Dec 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2018 --> Oct 2019
- | Trial completion, Trial primary completion date: B1B: Bright 1 Bodies Weight Management Program (clinicaltrials.gov) - May 31, 2018
P=N/A, N=50, Completed, Sponsor: Yale University
N=66 --> 0 | Trial completion date: Dec 2018 --> Dec 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2018 --> Oct 2019 Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> Oct 2017
- ||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - May 30, 2018
P1, N=2, Terminated, Sponsor: American CryoStem Corporation
Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> Oct 2017 N=100 --> 2 | Trial completion date: Jan 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> May 2018
- ||||| theralizumab (TAB08) / TheraMab
Trial completion date, Trial termination, Trial primary completion date: TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment (clinicaltrials.gov) - May 30, 2018
P2, N=60, Terminated, Sponsor: Theramab LLC
N=100 --> 2 | Trial completion date: Jan 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> May 2018 Trial completion date: Jun 2017 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> May 2018; Administrative reasons
- ||| Trial completion: VEGA Prospective Kiel (clinicaltrials.gov) - May 30, 2018
P=N/A, N=100, Completed, Sponsor: Aesculap AG
Trial completion date: Jun 2017 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> May 2018; Administrative reasons Recruiting --> Completed